GMDA – PDUFA (extended for review of data)

This event could be a big one for GMDA, options holders have put an IV of 60% or more on the shares based on how this event goes.  Runup Traders are probably going to have a play on this one in the weeks leading up to the event, as rumors are likely to be positive based on company comments when they submitted the data requested by the FDA.  Event traders are also going to want to monitor the results of the PDUFA.

However, as is per usual with PDUFA events, success from the FDA means the company has to fund the next stage, so Afterglow traders are going to want to tread lightly and maybe avoid chasing if they pop on the news.

Event PR: https://www.onclive.com/view/fda-extends-pdufa-date-for-bla-of-omidubicel-in-blood-cancers-requiring-transplant